Keyphrases
Indonesia
100%
Cervical Cancer Prevention
100%
Overall Survival
77%
Ovarian Cancer
66%
Cervical Cancer Screening
66%
Gynecologic Oncologist
57%
Tumor Patients
50%
Pelvic CT
50%
Obstetrics and Gynaecology
50%
Tertiary Referral Hospital
50%
Abdominal
50%
Free Survival
50%
High-risk Endometrial Cancer
50%
Large Uterine Fibroids
50%
Malignant Ovarian Tumor
50%
Fibroids
50%
Cervical Cancer Diagnosis
50%
Cesarean Hysterectomy
50%
Neutrophil-to-lymphocyte Ratio
50%
Cervical Cancer
50%
Fibrinogen
50%
Ratio Level
50%
Large Hospital
50%
Prognostic Value
50%
Lymphovascular Invasion
50%
Endometrioid
50%
Tertiary Hospital
47%
Hazard Ratio
38%
Cervical Cancer Patients
33%
Progression-free Survival
27%
Confidence Interval
27%
Developing Countries
25%
High-risk Human Papillomavirus (HR-HPV)
25%
Prognostic Factors
19%
January 2017
16%
Diagnostic Test
16%
Sensitivity Specificity
16%
Menopause
16%
General Hospital
16%
Multipara
16%
Silent Killer
16%
Surabaya
16%
Negative Predictive Value
16%
Positive Predictive Value
16%
Carbohydrate Antigen 125 (CA125)
16%
Liquid-based Cytology
16%
Abdominal CT
16%
Normal BMI
16%
Ovarian Malignancy
16%
Pathology Examination
16%
Medicine and Dentistry
Overall Survival
77%
Cervical Cancer
75%
Disease
70%
Ovarian Cancer
66%
Cervical Cancer Prevention
58%
Oncologist
57%
Pelvis
50%
Endometrial Cancer
50%
Uterine Fibroid
50%
Ovarian Tumor
50%
Patient Referral
50%
Uterine Myomectomy
50%
Malignant Neoplasm
50%
Cervical Cancer Screening
50%
Wart Virus
50%
Neutrophil
50%
Lymphocyte
50%
Fibrinogen
50%
Cancer Diagnosis
50%
Cancer Therapy
50%
Hazard Ratio
38%
Papanicolaou Stain
37%
Prognostic Factor
35%
Symptom
33%
Disease Free Survival
28%
Progression Free Survival
27%
Liquid-Based Cytology
25%
Wart Virus Vaccine
25%
Cervical Screening
25%
Genotype
25%
Body Mass Index
23%
Cancer
22%
Medical Record
16%
Sensitivity and Specificity
16%
Cross Sectional Study
16%
Diagnostic Test
16%
CA-125
16%
Outpatient
16%
General Practitioner
12%
Gynecological Oncology
8%
Therapy Delay
8%
Stage 3 Cancer
8%
Cancer Prevention
8%
Low and Middle Income Countries
8%
Biopsy
8%
Cancer Treatment
8%
Pfannenstiel Incision
7%
Log Rank Test
7%
Clinical Stage
7%
Myometrium
7%
